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Human cytomegalovirus (HCMV) is the prototypic beta-herpesvirus and widespread
throughout the human population. While infection is asymptomatic in healthy individuals,
it can lead to high morbidity and mortality in immunocompromised persons. Importantly,
HCMV evolved multiple strategies to interfere with immune cell function in order
to establish latency in infected individuals. As mature DCs (mDCs) are antigen-
presenting cells able to activate naïve T cells they play a crucial role during induction
of effective antiviral immune responses. Interestingly, earlier studies demonstrated that
the functionally important mDC surface molecule CD83 is down-regulated upon HCMV
infection resulting in a reduced T cell stimulatory capacity of the infected cells. However,
the viral effector protein and the precise mechanism of HCMV-mediated CD83 reduction
remain to be discovered. Using flow cytometric analyses, we observed significant
down-modulation of CD83 surface expression becoming significant already 12 h after
HCMV infection. Moreover, Western bot analyses revealed that, in sharp contrast to
previous studies, loss of CD83 is not restricted to the membrane-bound molecule, but
also occurs intracellularly. Furthermore, inhibition of the proteasome almost completely
restored CD83 surface expression during HCMV infection. Results of infection kinetics
and cycloheximide-actinomycin D-chase experiments, strongly suggested that an
HCMV immediate early gene product is responsible for the induction of CD83 down-
modulation. Consequently, we were able to identify the major immediate early protein
IE2 as the viral effector protein that induces proteasomal CD83 degradation.
Keywords: dendritic cells, HCMV, CD83, proteasomal degradation, IE2
INTRODUCTION
Dendritic cells (DCs) are known as professional antigen presenting cells because of their ability
to prime naïve T cells and thereby to induce effective antiviral immune responses. As immature
DCs they lay in wait in almost all peripheral tissues until antigen is encountered and taken up. As
a consequence DCs begin to mature and migrate along a chemokine gradient toward the draining
Frontiers in Microbiology | www.frontiersin.org 1 February 2017 | Volume 8 | Article 119
fmicb-08-00119 January 30, 2017 Time: 18:57 # 2
Heilingloh et al. HCMV-Induced CD83 Degradation on Mature DCs
lymph nodes for T cell activation. During maturation, expression
of MHC class I and II as well as of co-stimulatory molecules,
such as CD80, CD86 is upregulated (Banchereau and Steinman,
1998). Furthermore, expression of the surface molecule CD83,
which is one of the best maturation marker for DCs, is strongly
induced (Zhou and Tedder, 1996). In addition, CD83 is also
expressed on subsets of activated T cells, B cells, as well
as on neutrophils, thymus epithelial cells and on regulatory
T cells (Kozlow et al., 1993; Fujimoto et al., 2002; Iking-
Konert et al., 2002; Wolenski et al., 2003; Kreiser et al., 2015).
Besides the above mentioned membrane bound CD83 molecule
(mCD83) also a soluble form of CD83 (sCD83) has been
described. This sCD83 is released from activated DCs as well
as from B cells and is detectable at low levels in sera of
healthy individuals (Hock et al., 2001) and at elevated levels
in patients suffering from hematological malignancies (Hock
et al., 2004). The immunosuppressive effect of sCD83 was
shown in different animal models for autoimmune diseases
as well as in transplantation models (Zinser et al., 2004;
Ge et al., 2010; Lan et al., 2010; Bock et al., 2013; Eckhardt et al.,
2014).
In contrast to sCD83, mCD83 expressed on mDCs has been
suggested to have co-stimulatory properties, since knockdown
experiments of mCD83 using an siRNA approach in DCs resulted
in a significantly reduced T cell stimulatory capacity of these
DCs (Aerts-Toegaert et al., 2007; Prechtel et al., 2007). Therefore,
with respect to these studies showing the functional importance
of CD83, it is not surprising that several viruses, especially
herpesviruses, target CD83 upon infection of mDCs. Herpes
simplex virus type 1 (HSV-1), varicella-zoster virus and also the
human cytomegalovirus (HCMV) reduce the surface expression
of CD83 significantly. This in turn results in an inhibited T
cell proliferative capacity and therefore in a reduced antiviral
immune response (Kruse et al., 2000; Morrow et al., 2003;
Senechal et al., 2004).
Human cytomegalovirus is the most complex representative
within the herpesviruses and belongs to the Betaherpesvirinae
subfamily. Characteristic features of HCMV are the high
species specificity, a prolonged replication cycle, formation of
enlarged cells (cytomegaly) and the establishment of latent
infections in CD14+ monocytes and their CD34+ myeloid
progenitor cells (Whitley, 1996; Jackson et al., 2011; Rossetto
et al., 2013). In healthy immunocompetent adults primary
infection is usually asymptomatic. However, primary HCMV
infection or reactivation from latency in immunocompromised
individuals can lead to the development of life- and sight-
threatening diseases including hepatitis, pneumonitis, retinitis,
encephalitis, or gastroenteritis (Rubin, 1998; Landolfo et al.,
2003). Moreover, HCMV is presently the leading cause of
virus-associated birth defects including mental retardation,
blindness, or hearing loss (Chavanas, 2016). HCMV infects
a remarkably broad cell range including parenchymal cells
and connective tissue cells of almost any organ as well as
various hematopoietic cell types. Targets for viral replication are
predominantly fibroblasts and smooth muscle cells as well as
epithelial and endothelial cells (Sinzger, 2008; Revello and Gerna,
2010). Viral gene expression occurs in a temporally regulated
cascade that is subdivided into three sequential phases termed
immediate early (IE), early (E), and late (L; Wathen and Stinski,
1982).
Specifically, the tegument protein pp71, which is released into
the host cell during viral entry, is capable to induce expression
of IE genes, particularly UL122 (IE2) and UL123 (IE1), which
are encoded by the major IE locus (Kalejta, 2008). Both, IE1
and IE2, cooperate in initiation of viral early and late gene
expression and consequently play an important role in regulation
of HCMV infection (Malone et al., 1990). While IE2 is absolutely
essential for progression of the infectious cycle from IE to
E phase, HCMV mutants defective in IE1 expression show a
severe growth defect (Greaves and Mocarski, 1998). Therefore
it is thought that IE2 plays a crucial role in triggering the
lytic replication cycle of HCMV (Marchini et al., 2001). During
reactivation the infection is under control of the immune system
but the virus cannot be eliminated completely. However, besides
the establishment of latency HCMV has developed additional
strategies to escape the host’s immune response. Examples are
the degradation of newly synthesized MHC class I heavy chains
and the down-modulation of MHC class II molecules (Jones
et al., 1995; Hegde et al., 2003). Down-regulation of MHC class
I and II molecules restricts presentation of viral antigens and
thus limits elimination of the virus by the human immune
system (Noriega et al., 2012). An additional and different escape
mechanism of HCMV has been reported by Senechal et al. (2004).
This group postulated that HCMV infection of mDCs mediates
shedding of the immunosuppressive soluble CD83 molecule
into the supernatant which subsequently leads to a reduction
of DC-mediated antiviral T cell stimulation (Senechal et al.,
2004).
In contrast, in the present study we show that HCMV infection
of mDCs leads to the degradation of CD83 in a proteasome
dependent manner. Furthermore, we were able to show that the
immediate early protein 2 (IE2) is sufficient to induce CD83
degradation even in the absence of any other viral factor.
MATERIALS AND METHODS
Virus Strains, Virus Preparation, and
Virus Titration
In these studies the HCMV TB40E/IE2-EYFP strain expressing
IE2-EYFP fusion protein (Wagenknecht et al., 2015) and the
HCMV TB40E/UL84Pr-luc expressing luciferase under the
control of the UL84 promoter were used.
Virus stocks were prepared by infection of human foreskin
fibroblasts (HFFs) with the respective viral strain. HFFs were
cultured in Dulbecco’s minimal essential medium (DMEM;
Lonza, Basel, Switzerland) supplemented with 10% FCS (PAA,
Cölbe, Germany), 2 mM L-glutamine (Lonza), 100 U/ml
penicillin (Lonza), and 100 U/ml streptomycin (Lonza) until
a complete cytopathic effect was achieved. Cellular debris was
removed by centrifugation and virus containing cell culture
supernatant was stored−80◦C.
Virus titers for HCMV strains were determined as described
elsewhere (Andreoni et al., 1989; Wagenknecht et al., 2015).
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Generation of Mature Dendritic Cells
(mDCs)
Monocyte-derived DCs were generated as described previously
(Heilingloh et al., 2014). In brief, peripheral blood mononuclear
cells (PBMCs) were isolated from different healthy donors using
a Lymphoprep gradient (Nycomed Pharma AS, Oslo, Norway)
and afterward monocytes were separated using plastic adherence.
By addition of 800 U/ml granulocyte macrophage-colony
stimulating factor (GM-CSF; CellGenix, Freiburg, Germany)
and 250 U/ml IL-4 (Milteny, Bergisch-Gladbach, Germany)
monocytes differentiated to immature DCs. Maturation was
induced by adding 10 ng/ml TNF-α (Beromun, Boehringer
Ingelheim, Germany), 1 mg/ml prostin E2 (PGE2; Pfizer, NY,
USA); 200 U/ml IL-1β (CellGenix), 40 U/ml GM-CSF, 1000 U/ml
IL-6 (CellGenix), and 250 U/ml IL-4 to the medium. The
maturation status was controlled by flow cytometry, and mDCs
were used for further experiments.
Infection Procedure
For infection of mDC, 5× 105 cells, as a maximum, were washed
with PBS and resuspended directly in virus stock at a multiplicity
of infection (MOI) of 2. For mock-infected samples, mDCs were
resuspended in the equal volume of DMEM supplemented with
10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin. Infection was performed in a microcentrifuge at
23 × g for 1 h at room temperature. Subsequently, cells were
transferred into a 24 well plate and Roswell Park Memorial
Institute medium (RPMI 1640, Lonza) supplemented with 1%
autologous serum (Sigma Aldrich, Deisenhofen, Germany),
10 mM HEPES (Lonza), 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, 40 U/ml GM-CSF, and 250 U/ml IL-4
was added to a final volume of 0.5 ml.
Immunofluorescence Confocal
Microscopy
Mock- or HCMV-infected mDCs were allowed to adhere on
poly-L-lysin (Sigma Aldrich) coated glass cover slips, fixed
with 4% paraformaldehyde and permeabilized using 0.2%
Triton-X-100. Blocking was performed using 1% BSA in
PBS. Antibodies used for Immunofluorescence staining: anit-
CD83 (HB15a; Beckmann Coulter, Brea, USA); AlexaFluor647-
conjugated secondary antibody (Invitrogen, Carlsbad, CA, USA).
For mounting and additional nuclear staining Roti R©-Mount
FluorCare DAPI (Carl Roth) was used. Confocal microscopy
was performed using a LSM780 microscope (Zeiss, Oberkochen,
Germany).
Inhibitors
Proteasome inhibitors MG-132 (Enzo Life Sciences, Lörrach,
Germany), Epoxomicin (Enzo Life Sciences), and Bortezomib
(Santa Cruz Biotech. Inc, Heidelberg, Germany) were added 1 h
post-infection (hpi) at a final concentration of 10, 5, and 2 µM,
respectively.
Cycloheximide (CHX) and actinomycin D (ActD; Sigma
Aldrich) were used at a final concentration of 100 and 5 µg/ml,
respectively.
Flow Cytometric Analysis and Cell
Sorting
Detection of YFP expression of HCMV and changes in
expression of cell surface molecules were analyzed by flow
cytometry using antibodies specific for CD83 (clone HB15e; BD
Biosciences, Heidelberg, Germany), CD80 (clone L307.4; BD
Biosciences), and HLA-DR (clone G46-6, BD Biosciences). To
assure analysis of living cells, samples were additionally stained
using LIVE/DEAD R© Fixable Violet Dead Cell Stain Kit (Life
Technologies, Carlsbad, CA, USA). Unstained cells were used as
negative control.
Cells were sorted based on their YFP expression using a BD
Aria FACS Sorter (BD Biosciences).
Western Blotting
Mature DCs (mDCs; 1 × 106) were harvested and resuspended
in 50 µl lysis buffer (10% glycerol, 2 mM EDTA, pH 8,
137 mM NaCl, 10 mM sodium phosphate, pH 7.2, 1% NP-40,
2 mM phenylmethanesulfonyl fluoride, 20 mM sodium fluoride).
After 20 min on ice, lysates were cleared by centrifugation
at 4◦C and full speed for 20 min. Protein samples were
separated using SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and subsequently transferred onto a nitrocellulose
membrane. After blocking with 5% (w/v) dry milk or 1x
RotiBlock (Carl Roth, Karlsruhe, Germany) the membrane
was incubated with the primary antibody at 4◦C overnight.
After incubation with the appropriate secondary HRP-labeled
antibody, detection was performed using Amersham ECL Prime
Western Blotting Detection Reagent (GE Healthcare, Solingen,
Germany). The following primary antibodies were used for
Western blot analyses: anti-CD83 (clone F-5, Santa Cruz Biotech
Inc., Heidelberg, Germany, 1:1000), anti-β-actin (clone AC-74,
Sigma Aldrich; 1:2000), anti-GAPDH (clone 6C5, Millipore,
Schwalbach, Germany), and anti-CMV pp86 (IE2, clone 12E2,
Santa Cruz Biotech Inc; 1:1000).
ELISA for Detection of Soluble CD83
(sCD83)
Soluble CD83 levels were determined using a sandwich ELISA.
Ninety-six-well plates (Maxisorp; Nunc, Thermo Scientific) were
pre-coated for 1 h at 37◦C with anti-CD83 (clone HB15a,
Beckman Coulter, Brea, CA, USA), blocked with 10% goat
serum (Life Technologies), and finally samples were added.
After an overnight incubation at 4◦C wells were incubated
with 10 µg/ml rabbit-anti-CD83 (Sigma Aldrich) in diluent
(5% goat serum, 5% mouse serum, and 1% non-fat dry
milk in PBS) for 1 h at 37◦C. Next, wells were incubated
with goat-anti-rabbit-biotin (Dako, Eching, Germany, 1:5000)
for 1 h at 37◦C following a 1 h incubation at 37◦C
with streptavidin-HRP (Dako, 1:2000) in 0.5% BSA in PBS.
Between each antibody incubation step, plates were thoroughly
washed with 0.1% Tween 20 in PBS. Standard curves for
the estimation of sCD83 concentration were generated using
serial dilutions of recombinant sCD83 and the results were
expressed as a protein concentration based on the protein
standard. Plates were developed using BD OptEIA (BD
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Biosciences) and measured using a Tecan infinite R© F500 plate
reader.
CHX-ActD Chase Experiment
Mature DCs were mock-infected or infected with HCMV
TB40E/IE2-EYFP at an MOI of 2 in presence of 100 µg/ml
CHX. Cells were cultured in RPMI 1640 supplemented with
1% autologous serum, 10 mM HEPES, 2 mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin, 40 U/ml GM-CSF,
250 U/ml IL-4, and 100 µg/ml CHX. After a 6 h incubation at
37◦C, mDCs were washed twice in RPMI 1640 supplemented
with either 5 µg/ml ActD or the equal volume of DMSO and
cultured for additional 16 h as described above in the presence
of ActD or DMSO, respectively. Finally, cells were harvested and
surface expression of CD83 was analyzed by flow cytometry. The
efficiency of blocking early gene expression was controlled by
infection of mDCs with HCMV TB40E/UL84Pr-luc treated in
parallel as described above, using a luciferase reporter assay.
Luciferase Reporter Assay
Luciferase activity of HCMV TB40E/UL84Pr-luc infected mDCs
was performed in triplicates using the Dual-Luciferase Reporter
Assay System (Promega, Mannheim, Germany) according to
the manufacturer’s recommendations. The relative luminescence
units (RLU) were determined using the Tecan infinite R© F500 plate
reader.
Electroporation of mDC with DNA
Mature DC (3 × 106) were electroporated with 3 µg
of the IE2-expression vector pHM134 (Lang et al., 1995)
using P3 Primary Cell 4D-Nucleofector R© X Kit (Pulse: EH-
100) and the 4D-Nucleofector Device (Lonza) according to
the manufacturer’s instructions. After electroporation, the
nucleovette was immediately flushed with 500 µl warm RPMI
1640 (Lonza) and cells were transferred to a 24-well tissue
culture plate. RPMI 1640 supplemented with 1% autologous
serum, 10 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, 40 U/ml GM-CSF, and 250 U/ml IL-
4 were added at a final concentration of 0.5 × 106 cells/ml and
mDCs were incubated for 18–20 h.
Statistical Analyses
Results are displayed as means ± standard deviation (SD).
For multiple comparisons, data were analyzed using One-Way
ANOVA and Bonferroni’s Multiple Comparison post hoc test. For
comparison of two data sets p-values were determined using the
student’s t-test. Significance was accepted if p was <0.05.
Approvals and Legal Requirements
For the generation of monocyte-derived DCs from leukapheresis
products of healthy donors, a positive vote from the local ethics
committee has been obtained (reference number 4556). This
study was carried out in accordance with the recommendations
of the ethics committee of the “Friedrich-Alexander-Universität
Erlangen-Nürnberg” with written informed consent from
all subjects. All subjects gave written informed consent in
accordance with the Declaration of Helsinki.
RESULTS
Senechal et al. (2004) reported that infection of mDCs with
HCMV leads to a loss of CD83 cell surface expression
which finally results in a blocked T cell activation. As a
mechanism they suggested that a soluble form of CD83 is
shed from the cell surface and that this soluble form, which
has immunosuppressive properties (Lechmann et al., 2001), is
released into the supernatant, however, the precise mode of action
was not known (Senechal et al., 2004). Therefore, the aim of this
study was to further investigate the mechanisms underlying the
down-modulation of CD83 after HCMV infection of mDCs.
For the following experiments the recombinant HCMV
TB40E/IE2-YFP expressing an IE2-EYFP fusion protein was
used (Wagenknecht et al., 2015). This virus strain allows direct
analyses of HCMV positive mDCs despite a relatively low
infection efficiency of about 15% (Figure 1A). In order to analyze
whether the loss of CD83 from the cell surface of mDCs after
HCMV infection is a CD83 specific effect or due to a general
down-regulation of mDC surface proteins, mDCs were either
HCMV-infected or were left uninfected. After 16 h of incubation
cells were harvested and HCMV positive mDCs were screened
for CD83, CD80, and HLA-DR surface expression (Figure 1B,
white bars) in comparison to mock infected mDCs (Figure 1B,
black bars) using flow cytometry. While CD83 surface expression
was significantly reduced (p < 0.001), CD80 and HLA-DR were
not influenced by HCMV infection. These data confirmed that
CD83 is specifically down-modulated upon infection of mDCs
with HCMV.
Senechal et al. (2004) reported that CD83 is lost from the
cell surface but intracellular CD83 levels are not influenced.
To verify these observations mDCs were mock- or HCMV-
infected, and after 16 h of incubation, cells were sorted for
HCMV-positive (YFP+) and HCMV-negative (YFP−) cells.
Samples were subjected to Western blot analyses for detection
of CD83 expression (Figure 1C, top panel). IE2-expression
was also analyzed to verify the purity of the sorting process
(Figure 1C, middle panel) and β-actin was used as loading
control (Figure 1C, bottom panel). Compared to mock as well
as HCMV-negative mDCs (YFP−) which show a clear signal for
CD83, HCMV-positive cells (YFP+) lost CD83 nearly completely.
Additionally, immunofluorescence analyses of mock- or HCMV-
infected mDCs 16 hpi also showed an overall reduction of CD83
expression levels upon infection (Figure 1D). These data indicate
that CD83 is not only shed from the cell surface but also lost
inside the cell, suggesting an additional mechanism for CD83
down-modulation.
CD83 Is Degraded via a
Proteasome-Dependent Mechanism
It has previously been reported that HSV-1-induced CD83
degradation after infection of mDCs can be prevented by
inhibition of the proteasome (Kummer et al., 2007). To
investigate whether a similar mechanism is responsible for
HCMV-induced CD83 down-modulation, infection experiments
using proteasome inhibitors were performed. First, mDCs were
Frontiers in Microbiology | www.frontiersin.org 4 February 2017 | Volume 8 | Article 119
fmicb-08-00119 January 30, 2017 Time: 18:57 # 5
Heilingloh et al. HCMV-Induced CD83 Degradation on Mature DCs
FIGURE 1 | Human cytomegalovirus infection induces specific CD83 reduction. Mature DCs (mDCs) were mock- or HCMV-infected. After 16 h, cells were
harvested and HCMV-infected as well as mock-infected mDCs were analyzed for their CD83 expression by flow cytometry. (A) Gating strategy for flow cytometric
analyses. HCMV positive cells were directly analyzed by gating for their IE2-YFP expression. (B) Summary of three independent experiments performed with cells of
different healthy donors. Cells were stained for their surface expression of CD83, CD80 and HLA-DR (MHC class II). Significant changes are indicated by asterisks
(∗∗∗p < 0.001). (C) mDCs were mock- or HCMV-infected. After 16 h of infection cells were harvested and HCMV-positive cells (YFP+) were separated from HCMV
negative mDCs (YFP−) by sorting, based on YFP expression. Subsequently, cells were lysed and analyzed by Western blot for their CD83 expression using a
CD83-specific antibody. An IE2-specific antibody was used to verify the purity of the sorted samples and a β-actin antibody was used to assure equal loading. The
experiment was performed at least three times and representative data are shown. (D) mDCs were mock- or HCMV-infected and after 16 h cells were analyzed for
their CD83 expression levels via immunofluorescence. HCMV positive cells were identified based on their IE2-YFP expression. Dapi was used for visualization of the
nucleus. One representative experiment out of four is shown.
mock-infected or HCMV-infected and 1 hpi, cells were treated
with different proteasome inhibitors (10 µM MG-132, 2 µM
Bortezomib, or 5 µM Epoxomicin) or DMSO as control. After
16 h, mDCs were analyzed for their CD83 surface expression
by flow cytometry (Figures 2A,B). Figure 2A shows the results
of one representative experiment while Figure 2B illustrates
the results of three independent experiments performed with
cells of different healthy donors. Mock-samples (Figure 2A, gray
histograms and Figure 2B, black bars) show no CD83 reduction
whereas in the HCMV positive sample without any inhibitor a
significant CD83 reduction (p< 0.001) was observed. In contrast,
treatment with proteasome inhibitors MG-132, Bortezomib or
Epoxomicin prevented CD83 down-modulation, demonstrating
that CD83 is degraded via the proteasome (Figure 2A, gray filled
histograms and Figure 2B, white bars).
In a next step, we were wondering if the observed proteasomal
degradation of CD83 takes place in parallel to the proposed
shedding of a soluble form of CD83 (sCD83) from the cell surface.
Therefore, we determined the levels of sCD83 in the supernatant
of the HCMV-infected mDC cell culture. In sharp contrast to the
data reported by Senechal et al. (2004), we observed no difference
regarding the sCD83 levels in HCMV-infected samples compared
to mock samples. Treatment with MG-132 led to an overall and
therefore unspecific increase of sCD83 levels in the supernatant
of mock- as well as HCMV-infected cells (Figure 2C).
These data indicate that CD83 is not shed from the cell surface
of HCMV-infected mDCs but rather degraded via the cellular
proteasome.
An Immediate Early Gene Product Is
Responsible for HCMV-Mediated CD83
Degradation
To further elucidate the mechanism leading to CD83 reduction
after HCMV infection of mDCs, we aimed to identify the effector
protein/s inducing CD83 down-modulation. To narrow down the
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FIGURE 2 | CD83 down-modulation can be prevented by inhibition of the proteasome. mDCs were mock- or HCMV-infected. One hour post-infection (hpi)
cells were treated either with DMSO or with 10 µM MG-132, 2 µM Bortezomib, or 5 µM Epoxomicin. After additional 16 h of incubation cells were harvested and
analyzed for their CD83 surface expression using flow cytometry. (A) Results of flow cytometric analyses. Overlays of mock sample (dark gray histogram),
HCMV-infected sample (filled gray histogram) and unstained condition (black histogram), as negative control, are shown. The experiment was performed three times
and representative data are shown. (B) Summary of three independent experiments performed as described above. Mock-infected cells (black bars) were used as
controls and treated in the same way as HCMV-infected samples (white bars). Significant changes (∗∗∗p < 0.001) are indicated by asterisks. (C) Detection of soluble
CD83 by ELISA in the supernatant of mock- or HCMV-infected mDCs. mDCs were infected as described above and treated with or without 10 µM MG-132 1 hpi.
After additional 16 h the supernatant was harvested and analyzed for their soluble CD83 content using ELISA. Mock- and HCMV-infected samples are depicted as
black and white bars, respectively.
phase of the viral replication cycle in which CD83 loss occurs,
an infection time course experiment was performed. Therefore,
mDCs were mock- or HCMV-infected and analyzed for CD83
expression at different time points post-infection using flow
cytometry (Figure 3A). HCMV infection efficacy was determined
in parallel by measuring YFP-expression (Figure 3B). Figure 3A
illustrates CD83 reduction in HCMV-infected mDCs (white bars)
in comparison to the mock control (black bar). After 12 h a
significant loss of CD83 (p < 0.001) could be observed. At this
time point only 50% of the infected cell population showed
CD83 expression. CD83 reduction increased over time and after
24 h only 15% of mDCs expressed CD83. This CD83 down-
modulation was paralleled by the increase of YFP expression,
reflecting expression of IE2 (Figure 3B).
Taken together these observations clearly suggest a correlation
between IE gene expression and CD83 down-modulation, leading
to the hypothesis that the viral effector might be expressed in the
IE or early phase of the HCMV replication cycle.
Knowing that a gene product of the IE or early phase is
most likely responsible for the down-modulation of CD83, we
further wanted to differentiate a possible IE effect from an early
effect. The replication cycle of HCMV, as for all herpes viruses,
is a strictly regulated cascade of three phases. First, IE gene
products are expressed and these IE proteins are required to
initiate expression of early (E) genes. The proteins of the E
phase are then needed to initiate the expression of late genes.
This feature can be used to discriminate between IE and E gene
effects performing a cycloheximide-ActD-chase experiment. In
brief, mDCs were mock- or HCMV-infected in the presence of
DMSO as control or 100 µg/ml cycloheximide (CHX). This CHX
treatment prevents protein translation of viral genes but allows
gene transcription. After 6 h of incubation, CHX was washed
out and cells were incubated in DC-medium, containing either
5 µg/ml ActD or DMSO (as a control) for additional 16 h. ActD
allows translation of already existing mRNAs, but prevents the
synthesis of new mRNAs. At the end of incubation, cells were
harvested and stained for their CD83 surface expression.
In Figure 4A the results of the CHX-ActD-chase experiment
are illustrated. Mock controls are depicted in black, HCMV-
infected samples in white. CD83 was reduced significantly in
CHX-DMSO-treated HCMV positive cells as well as in DMSO-
treated cells. In these settings, gene products of all phases are
present. In CHX-ActD-treated samples an overall reduction
of CD83 surface expression is already observed in mock-
infected cells. Nevertheless, there is a significant reduction of
CD83 (p < 0.05) in HCMV positive CHX-ActD-treated mDCs
compared to the mock control indicating that IE gene products
are involved in the loss of CD83.
To verify inhibition of the expression of early and late genes by
the afore described experiment, cells were infected in parallel with
virus strain HCMV TB40E/UL84Pr-luc encoding a luciferase
gene under the control of the promoter of the early gene UL84,
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FIGURE 3 | Significant CD83 down-modulation occurs already 12 h
after HCMV infection. mDCs were mock- or HCMV-infected, harvested at
indicated time points and analyzed by flow cytometry. (A) DCs were stained
for CD83 surface expression. Mock-controls were set to 100% (black bar) and
relative CD83 surface expression of HCMV-infected mDCs (white bars) is
shown. Significant changes (∗∗∗p < 0.001) are indicated by asterisks and
non-significant changes (p > 0.05) are labeled as “ns.” (B) At indicated time
points cells were analyzed for YFP expression and percentages of HCMV
positive mDCs are shown. Experiments were performed three times with cells
from different healthy donors.
and treated as described above. At the end of the incubation
period a luciferase assay was performed (Figure 4B). Mock-
infected mDCs served as negative control (Figure 4B, black
bars). DMSO as well as CHX-DMSO-treated samples show high
luciferase activity whereas CHX-ActD-treated mDCs show a
luminescence intensity similar to mock-infected cells, confirming
that expression of E genes and in turn L genes is inhibited.
IE2 Is Sufficient to Induce CD83
Down-Modulation
Since our data suggested that an IE gene product is responsible
for the induction of CD83-degradation, and the knowledge that
levels of the IE protein IE2 increased in parallel to the loss of
CD83, we next checked whether IE2 is able to induce CD83-
degradation. For this purpose mDCs were electroporated with
an IE2 expression plasmid and treated with or without MG-132.
As mock control, cells were pulsed but without addition of any
DNA (EP only). After 20 h, cells were harvested and analyzed
via flow cytometry and Western blotting (Figure 5). Figure 5A
FIGURE 4 | An immediate early gene product is responsible for the
induction of CD83 degradation. (A) mDCs were mock- or HCMV-infected
in presence of Cycloheximide (CHX) to inhibit translation or DMSO serving as
negative control. Six hpi, CHX was replaced by ActD, inhibiting transcription,
or DMSO as control. After an additional 16-h incubation, cells were harvested
and analyzed for their CD83 surface expression by flow cytometry. Significant
changes are indicated by asterisks (∗p < 0.05; ∗∗∗p < 0.001), non-significant
changes (p > 0.05) as “ns.” Mock controls are depicted as black bars and
HCMV-infected samples are shown in white. (B) mDCs were infected with
HCMV TB40E/UL84Pr-luc to verify the inhibition of early genes during the
CHX-ActD-chase experiment. Cells were treated as described above. After
16 h of incubation, cells were harvested and a luciferase assay was
performed. The luminescence intensities of mock-samples (black bars) and
HCMV-infected samples (white bars) are shown. The experiment was
performed three times with cells from different donors and significant changes
(∗∗∗p < 0.001) are indicated by asterisks. Non-significant changes (p > 0.05)
are depicted as “ns.”
illustrates the analysis of CD83 surface expression. IE2 positive
cells showed a highly significant (p< 0.0001) down-regulation of
CD83 surface expression (Figure 5A, white bar) which could be
prevented by the addition of the proteasome inhibitor MG-132
(Figure 5A, gray bar). CD80 and HLA-DR were used as control
and were not affected in the presence of IE2. Western blot analysis
confirmed the results of flow cytometry analysis and verified
expression of IE2 (Figure 5B, top and middle panel, respectively).
GAPDH was used as loading control (Figure 5B, bottom panel).
In order to investigate whether IE2 co-localizes with CD83
in HCMV-infected mDCs, which would suggest that IE2
induces CD83-degradation via a direct interaction, we performed
immunofluorescence analyses (Figure 5C). Therefore, mDCs
were mock- or HCMV-infected, treated with or without MG-
132 and analyzed for their CD83 as well as IE2 expression. The
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FIGURE 5 | IE2 is sufficient to induce CD83 degradation in mDCs. mDCs (3 × 106) were electroporated with 3 µg DNA of an IE2 expressing plasmid (white
bars) or were pulsed without addition of DNA as negative control (EP only; black bars). Directly after electroporation mDCs were treated with or without MG-132 and
incubated for 16 h. (A) Cells were analyzed for their surface expression of CD83, CD80, and HLA-DR using flow cytometry. The experiment was performed at least
five times with cells from different healthy donors. Significant changes are indicated by asterisks (∗∗∗p < 0.001; ∗∗∗∗p < 0.00001). (B) Western Blot analysis for
CD83 and IE2 expression. GAPDH was used as internal loading control. The experiment was conducted three times with cells from different donors and
representative data are shown. (C) mDCs were mock- or HCMV-infected, treated with or without MG-132 and analyzed for their CD83 expression levels using
immunofluorescence 16 hpi. The IE2-YFP fusion protein allows direct visualization of IE2 expression as well as localization in HCMV positive cells. The nucleus was
visualized using Dapi. The experiment was performed four times and representative data are shown.
treatment of HCMV-infected mDCs with MG-132 restored CD83
expression reaching levels of the respective mock-condition.
However, no co-localization of IE2 and CD83 was observed in
the context of an HCMV-infection hinting toward an indirect
mechanism for IE2-induced CD83-degradation.
Taken together these data clearly demonstrate that HCMV
infection of mDCs does not lead to a shedding of a soluble form
of CD83 from the cell surface but to proteasomal degradation
of CD83. Furthermore, we were able to show that the major IE
protein IE2 is sufficient to induce this degradation even in the
absence of any additional viral factor.
DISCUSSION
In the present study, we report that upon HCMV infection of
mDCs CD83 surface expression is reduced with fast kinetics,
becoming significant already 12 h after infection and reaching
its maximum 16 hpi. Interestingly, other mDC surface markers
such as CD80 and MHC class II were not affected during the
observation period. This is in line with results obtained from
HSV-1-infected mDCs in which CD83 is also rapidly down-
modulated while the expression of co-stimulatory molecules
such as CD80 and CD86 are not influenced (Kruse et al., 2000;
Kummer et al., 2007). In addition, it has been described that
infection of mDCs with HCMV results in down-regulation of
MHC class I as well as MHC class II molecules. This reduction,
however, is not detectable until 72 hpi (Benz et al., 2001; Sinzger
et al., 2006). CD83 degradation specifically occurs very early
after infection supporting the hypothesis that CD83 is involved
in mechanisms important for the initiation of antiviral immune
responses especially for T cell activation (Kruse et al., 2000;
Scholler et al., 2002; Hirano et al., 2006). The fact that several
viruses, especially herpesviruses, directly target CD83 points to
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the importance of this molecule in the establishment of antiviral
immunity (Kruse et al., 2000; Morrow et al., 2003; Senechal et al.,
2004).
Here, we clearly demonstrated that CD83 is not lost from
the cell surface of mDCs upon HCMV infection but that it
is rapidly degraded via a proteasome-dependent mechanism.
This observation is in sharp contrast to the result of Senechal
et al. (2004). They suggested that infection of mDCs leads
to a reduction of merely CD83 surface expression most
probably caused by shedding of a soluble form of CD83
which in turn might be responsible for the diminished T cell
stimulatory capacity (Senechal et al., 2004). However, using
several proteasome inhibitors we observed that CD83 levels
can be restored nearly completely, demonstrating that CD83
is degraded in a proteasome-dependent manner, as previously
described for HSV-1-infected mDCs (Kummer et al., 2007). We
additionally analyzed the supernatants of HCMV infected mDCs
for sCD83 levels to address the question whether shedding occurs
in parallel with degradation of CD83 as a combined mechanism
to rapidly down-modulate CD83 from the cell surface. However,
we were not able to detect any differences in sCD83 levels released
from HCMV infected mDCs compared to mock-treated cells. As
several reports demonstrated that inhibition of the proteasome
using MG-132 can activate as well as further induce shedding of
proteins, e.g., shown for TNF-α receptors (Levine et al., 2005;
Peiretti et al., 2005; Ortiz-Lazareno et al., 2008), we analyzed
supernatants from HCMV-infected mDCs treated with MG-
132 as well. We observed an increased release of CD83 in the
supernatant, but again no differences between mock and HCMV-
infected mDCs could be detected confirming our conclusion
that CD83 is degraded and not shed from the cell surface. The
observed discrepancy concerning sCD83 release between the
present study and the work performed by Senechal et al. (2004)
might be due to the use of different HCMV strains or the analysis
at different time points post-infection.
In order to identify a possible viral effector inducing CD83
down-modulation, we first determined the replication phase
in which this candidate protein is expressed. A time course
experiment performed with HCMV-infected mDCs indicated a
viral gene product that is present already at a very early time point
after infection. We confirmed this hypothesis using a CHX-ActD-
chase experiment in which only IE gene products were expressed.
Results obtained from this experiment supported the hypothesis
that CD83 reduction occurs during the IE replication phase
and that the viral effector inducing CD83 down-modulation is
expressed in this phase. Supported by the fact that levels of the IE
protein IE2 increased in parallel to the loss of CD83 we analyzed
the effect of this protein on CD83 in more detail. By directly
expressing IE2 in mDCs we were able to provide evidence, that
this IE protein of HCMV is sufficient to induce CD83 degradation
in a proteasome dependent manner in absence of any other viral
factor.
Regarding the ability of IE2 to induce a degradation
mechanism very little is known so far. One study suggests that
IE2 directly binds its substrate Mdm2 (Mouse double minute 2
homolog) and thereby facilitates its degradation in a proteasome-
independent manner (Zhang et al., 2006). This mechanism can
be precluded for CD83 as this protein is degraded via the
proteasome. Beyond that, Khan et al. (2014) demonstrated that
IE2 is clearly involved in the induction of the proteasomal
degradation of connexin43. In addition, our localization studies
of CD83 and IE2 (Figure 5C) support the hypothesis that IE2 may
induce CD83 degradation in an indirect way by upregulating one
or more cellular proteins which subsequently target CD83 to the
proteasome.
CONCLUSION
The results of the present study demonstrate for the first time
that IE2 induces the down-modulation of CD83 very early after
HCMV infection of mDCs. In contrast to previous studies, we
observed an intracellular loss of CD83 which can be prevented
by the use of proteasome inhibitors indicating that reduction of
CD83 protein levels is mediated by proteasomal degradation.
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